Lyon (France), March 7, 2014 – European biotechnology company Valneva SE (Valneva) announced today that it has signed a new research license agreement and transferred an existing commercial agreement to Emergent BioSolutions Inc. (NYSE:EBS), to develop new vaccines using Valneva’s EB66® cell line.
